Kolexia
Delord Jean-Pierre Oncologie médicale
Delord Jean-Pierre
Oncologie médicale
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
428 Activités
178 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Tumeurs du poumon Métastase tumorale Carcinome pulmonaire à petites cellules Tumeurs colorectales Récidive tumorale locale

Collaborateurs

Voir plus
Gomez-Roca Carlos
Gomez-Roca Carlos
Oncopole Toulouse, Toulouse, France
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France
Cassier Philippe
Cassier Philippe
Centre Léon-Bérard, Lyon, France
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France

Industries

Voir plus
MSD
7 collaboration(s)
Dernière en 2023
Roche
1 collaboration(s)
Dernière en 2022
Parexel
1 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
IMMUNONET: A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies
Essai Clinique (NETRIS Pharma)   06 mars 2024
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors: A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors
Essai Clinique (Genentech)   27 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158): A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Essai Clinique (Merck & Co.)   02 février 2024
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma
JHEP reports : innovation in hepatology   28 janvier 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Science translational medicine   24 janvier 2024
MEDIOLA: A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors
Essai Clinique (AstraZeneca)   23 janvier 2024
FIPO23: Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors
Essai Clinique (Xenothera SAS)   19 janvier 2024
MINER: Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   05 janvier 2024
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity.
Scientific reports   18 décembre 2023